Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell ...
AZD4635 enhances immune activation and infiltration in vivo. (A) Mice ...
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab ...
AZD4635 (HTL1071) is a Selective and Orally Active A2AR Antagonist ...
(PDF) Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine ...
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A ...
AZD4635 (HTL1071) | CAS 1321514-06-0 | AbMole BioScience | AZD4635 Price
AZD4635 is a potent A 2A R antagonist. (A) Chemical structure of ...
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab ...
(PDF) Small molecule AZD4635 inhibitor of A 2A R signaling rescues ...
AZD4635 enhances the antitumor activity of checkpoint inhibitors in ...
(PDF) Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an ...
Comprehensive clinical pharmacology characterization of AZD4635 in ...
The TST, CPT‐S‐PEG, and AZD4635 were co‐assembled into nanoparticles ...
AZD4635 With Durvalumab or Oleclumab for Metastatic Castration ...
AZD4635 | Adenosine Receptor | TargetMol
AZD4635 CAS#: 1321514-06-0
Imaradenant (AZD4635) | Adenosine Receptor antagonist | CAS 1321514-06 ...
| Evaluation of combination strategies for AZD4635. (A) Identification ...
阿斯利康新药AZD4635 显著改善前列腺癌免疫治疗|前列腺癌|阿斯利康|血液腺苷|抵抗性|PFS|新药|免疫|胶囊|-健康界
Frontiers | Evaluation of Combination Strategies for the A2AR Inhibitor ...
(PDF) Evaluation of Combination Strategies for the A2AR Inhibitor ...
(PDF) Anti-tumor synergy evaluation of an AZD4635/anti-PD-L1combination ...
Sosei Heptares receives $15m for cancer therapy milestone
Opportunities for Small Molecules in Cancer Immunotherapy: Trends in ...
In vivo modulation of the adenosine pathway reduces tumor growth and ...
Frontiers | Adenosine-A2A Receptor Pathway in Cancer Immunotherapy
Frontiers | Clinical cancer immunotherapy: Current progress and prospects
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies ...
Small molecule-based immunomodulators for cancer therapy - PMC
RCSB PDB - 6GT3: Crystal Structure of the A2A-StaR2-bRIL562 in complex ...
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can ...
Synthetic Route Design of AZD4635, an A2AR Antagonist | Organic Process ...
A phase I, open-label, multicenter study to assess the safety ...
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese ...
Immunosuppressive immune subpopulations are modulated following ...
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy - PMC
Targeting the adenosinergic axis in cancer immunotherapy: Insights into ...
A new article was published in Frontiers in Immunology journal. - M&S
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and ...
Investigation of immunotherapy effect of different nanoparticles in ...
Clinical cancer immunotherapy: Current progress and prospects - PMC
(PDF) Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese ...
Structures of A 2A AR antagonists in clinical trials for cancer ...
Adenosine A2A receptor as a potential target for improving cancer ...
Ribbon Diagrams on Twitter: "6GT3: Crystal Structure of the A2A-StaR2 ...
Iridium- and Palladium-Based Catalysts in the Pharmaceutical Industry
Defining the spatial distribution of extracellular adenosine revealed a ...
Frontiers | In vitro models as tools for screening treatment options of ...
恒光讲堂｜动态调节AIE分子非辐射和辐射衰减以实现光热治疗和免疫治疗_纳米_颗粒_癌细胞
Using Oxygen as the Primary Oxidant in a Continuous Process ...
Discovery of the First Efficacious Adenosine 2A Receptor Negative ...
| Evaluation of tumor microenvironment (TME) dynamics across ...
Sosei Provides an Update on Its Immuno-Oncology Clinical Program with ...
Likang gets trial ok for China's first personalized cancer vaccine
